The American Journal of Medicine
Volume 123, Issue 5 , Pages 446-453 , May 2010

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

Parts of these data were presented in poster format at the Heart Rhythm Society Annual Meeting, May 13-16, 2009.

  • Peter J. Zimetbaum, MD

      Affiliations

    • Harvard Medical School, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Peter J. Zimetbaum, MD, Director, Clinical Cardiology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215
    • ,
  • Amit Thosani, MD

      Affiliations

    • Harvard Medical School, Boston, Mass
    • ,
  • Hsing-Ting Yu, MPH

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Yan Xiong, MS

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Jay Lin, PhD

      Affiliations

    • sanofi-aventis, Bridgewater, NJ
    • ,
  • Prajesh Kothawala, MD, MPH

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif
    • ,
  • Matthew Emons, MD, MBA

      Affiliations

    • Cerner LifeSciences, Beverly Hills, Calif

  • Image Result

    Patients meeting study inclusion/exclusion criteria.

    Patients meeting study inclusion/exclusion criteria.

  • Image Result

    Patients stratified by CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke) score.

    Patients stratified by CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke) score.

  • Image Result

    Warfarin use within 30 days of first recorded atrial fibrillation/flutter diagnosis, by stroke risk level. *Hatched area represents the proportion of patients with uninterrupted therapy over 180 days

    Warfarin use within 30 days of first recorded atrial fibrillation/flutter diagnosis, by stroke risk level. *Hatched area represents the proportion of patients with uninterrupted therapy over 180 days following their initial warfarin prescription. CHADS2=Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke score.

 Funding: Financial support for the preparation of this manuscript was provided by sanofi-aventis US, Inc. This funding was used for provision of editorial support by Elizabeth Harvey, PhD and Andrew Fitton, PhD of UBC Scientific Solutions.

 Conflict of Interest: Dr. Peter Zimetbaum is a research consultant to sanofi-aventis. Dr. Jay Lin is an employee of sanofi-aventis. Hsing-Ting Yu and Matthew Emons are employees of Cerner LifeSciences, which provided consulting services to sanofi-aventis. Yan Xiong and Prajesh Kothawala were employed by Cerner LifeSciences at the time the research was conducted.

 Authorship: All authors had access to the study data, and participated in analysis or interpretation of the data (or both), and preparation of the manuscript.

PII: S0002-9343(09)01114-0

doi: 10.1016/j.amjmed.2009.11.015

The American Journal of Medicine
Volume 123, Issue 5 , Pages 446-453 , May 2010

Article Tools

* Image Usage & Resolution